EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Characterization of Proteomic Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics to Inform Potential Utility in Biosimilar Development

Lakshmi Manasa S Chekka iD, Deepti P Samarth iD, Yan Guo, Esraa G Mohamed, Erica Decker iD, Murali K Matta, Qin Sun iD, William Wheeler, Carlos Sanabria, Joel Wommack, Joseph Gogain iD, Sarah J Schrieber und 4 weitere

Clinical Pharmacology & Therapeutics · 2025

DOI: 10.1002/cpt.3754 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Lakshmi Manasa S Chekka und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Proteomics, Interferon beta-1a, Interferon-beta. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pharmacodynamic (PD) biomarkers can support biosimilarity assessment, potentially reducing the need for comparative clinical efficacy studies. This study aimed to characterize previously identified proteomic PD biomarker candidates for Interferon beta‐1a (IFNβ‐1a, n = 248) and pegylated IFNβ‐1a (pegIFNβ‐1a, n = 528) biologics at therapeutic doses, to further evaluate the utility of proteomics in biosimilar development. Here, we reproduced the results at lower doses and characterized PD responses across multiple doses using criteria for justifying PD biomarker use in biosimilar development. We analyzed candidate proteins from longitudinal proteomics data (SomaScan™ Assay v4.1) from 48 healthy subjects administered intermediate or low doses of IFNβ‐1a (15, 7.5 μg) or pegIFNβ‐1a (62.5, 31.25 μg) in an FDA‐sponsored study, alongside previously published therapeutic dose and placebo data. EDTA plasma samples were collected at 0, 0.125, 0.33, 0.67, 1.33, 2, 3, 4, 5, 6 days and at 9, 13 days additionally for pegIFNβ‐1a. Prioritization criteria included significant differential expression at the intermediate dose vs. placebo, ≥20% response difference from placebo, significant baseline‐adjusted area under the effect curve (AUEC) and a monotonic dose–response relationship across all doses. Among the candidates, 165 and 323 were differentially expressed at intermediate doses of IFNβ‐1a and pegIFNβ‐1a respectively. Nine PD biomarkers, including C‐X‐C motif chemokine 11 (I‐TAC), Lymphocyte activation gene 3 protein (LAG3), and Granulins (GRN), were prioritized as common to both biologics. Most candidates followed the E max dose–response model. I‐TAC showed the strongest response, and LAG‐3 showed the least variability in AUEC. Our study identified several suitable plasma PD biomarkers for IFNβ‐1a and pegIFNβ‐1a biologics with potential utility in biosimilar development programs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosimilar PharmaceuticalsProteomicsInterferon beta-1aInterferon-betaPolyethylene GlycolsHumansMaleBiomarkersFemaleAdultDose-Response Relationship, DrugYoung AdultMiddle AgedDrug DevelopmentBiomarkers, Pharmacological

Substanzen

Biosimilar PharmaceuticalsInterferon beta-1aBiomarkersInterferon-betaPolyethylene Glycolspeginterferon beta-1aBiomarkers, Pharmacological

Autor:innen und Institutionen

  • Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Therapeutic Biologics Program, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
  • Information Management Services, Inc, Rockville, Maryland, USA.
  • Spaulding Clinical Research, West Bend, Wisconsin, USA.
  • Standard BioTools, Inc, Boulder, Colorado, USA.
  • Office of Therapeutic Biologics and Biosimilars, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID-Profile: Lakshmi Manasa S Chekka, Deepti P Samarth, Erica Decker, Qin Sun, Joseph Gogain, Yow-Ming Wang, David G Strauss

Zitieren

APA

Chekka, L. M. S., Samarth, D. P., Guo, Y., Mohamed, E. G., Decker, E., Matta, M. K., Sun, Q., Wheeler, W., Sanabria, C., Wommack, J., Gogain, J., Schrieber, S. J., Florian, J., Wang, Y. M., Strauss, D. G., & Hyland, P. L. (2025). Characterization of Proteomic Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics to Inform Potential Utility in Biosimilar Development. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3754

Vancouver

Chekka LMS, Samarth DP, Guo Y, Mohamed EG, Decker E, Matta MK, et al. Characterization of Proteomic Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics to Inform Potential Utility in Biosimilar Development. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3754

BibTeX
@article{Chekka2025,
  author = {Chekka, Lakshmi Manasa S and Samarth, Deepti P and Guo, Yan and Mohamed, Esraa G and Decker, Erica and Matta, Murali K and Sun, Qin and Wheeler, William and Sanabria, Carlos and Wommack, Joel and Gogain, Joseph and Schrieber, Sarah J and Florian, Jeffry and Wang, Yow-Ming and Strauss, David G and Hyland, Paula L},
  title = {Characterization of Proteomic Pharmacodynamic Biomarkers of IFNβ ‐1a Biologics to Inform Potential Utility in Biosimilar Development},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1002/cpt.3754}
}
Kostenlos starten →